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Abstract
The antitrypanosomal activities, cytotoxicity, and selectivity indices of eleven imido-substituted
1,4-naphthoquinone derivatives and nifurtimox have been studied. Compared to nifurtimox (IC50
= 10.67 µM), all the imido-naphthoquinone analogs (IMDNQ1-IMDNQ11) are more potent on
Trypanosoma cruzi with IC50 values ranging from 0.7 µM to 6.1 µM (p < 0.05). Studies of the
cytotoxic activities of these compounds on a Balb/C 3T3 mouse fibroblast cell line revealed that
four of these compounds, IMDNQ1, IMDNQ2, IMDNQ3, and IMDNQ10 displayed selectivity
indices of 60.25, 53.97, 31.83, and 275.3, respectively, rendering them significantly (p < 0.05)
more selective in inhibiting the parasite growth than nifurtimox (selectivity index = 10.86).
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INTRODUCTION
Chagas disease is a tropical disease caused by the protozoan Trypanosoma cruzi and
transmitted by triatomine bugs. It commonly occurs in poor and rural areas of Central and
South America. Chagas disease is expanding beyond its endemic area as a result of
migration from and to the endemic countries (Hanford et al., 2007; Hotez, 2008; Schofield
and Kabayo, 2008). American trypanosomiasis therapy mostly depends on drugs that were
developed decades ago, requires long term administration, and is not available to all patients
due to its high cost. Two drugs, Nifurtimox and Benznidazole (Fig. 1), are currently used to
treat only the acute phase of the infection where parasites (try-pomastigotes) are detectable
in the peripheral blood (Andrade et al., 2004; Schofield and Kabayo, 2008). Both drugs have
gastrointestinal and neurological side effects which may worsen as the patient ages (Nagel
and Nepomnaschy, 1983; Ferreira and Ferreira, 1986; Melo and Ferreira, 1990; Coura and
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de Castro, 2002). Consequently, alternative drugs with a more selective mode of action are
being investigated. Several classes of drug-like molecules have been studied for their
antitrypanosomal activity. One of the most interesting is the quinone family of compounds.
This class of compounds incorporates several diverse structural types including the
naphthoquinones, which are known to possess a number of useful biological activities
including antiviral, antifungal, antineoplastic, antihypoxic, anti-ischemic, antiplatelet, antiinflammatory, and antiallergic activities (Kartoflitskaya et al., 1997; Huang et al., 1998;
Tandon et al., 2004; Copeland et al., 2007). For instance, the naturally occurring
naphthoquinone, lapachol (Fig. 1), and some of its derivatives have been found to show
trypano-cidal activity against T. cruzi (Salas et al., 2008). Also, some naphthofuranquinones
synthesized from 2-hydroxy-3-allyl-1,4-naphthoquinone were found to be active against
epimastigote and trypomastigote forms of T. cruzi (Silva et al., 2006). In a recent study, a
series of naphthoquinones were assessed for their try-panocidal activity and 2,3diphenyl-1,4-naphthoquin-one (DPNQ) was found to be effective against T. cruzi
epimastigotes at a low micromolar concentration (LD50 = 2.5 µM) by inhibiting T. cruzi
lipoamide dehydro-genase (TcLipDH) (Ramos et al., 2009). Previously, Bakare et al. (2003)
and Berhe et al. (2008) reported a series of imido-substituted 1,4-naphthoquinones as a
unique class of mitogen activated protein kinase kinase 1 (MEK1) inhibitors with a number
of them showing anticancer activities. In pursuit of potent and more selective
antitrypanosomal agents, several imido-sub-stituted 1,4-naphthoquione (IMDNQ)
derivatives (Fig. 2) have been identified as a new class of anti-try-panosomal agent. This
new class of naphthoquinones has not been previously investigated as an antitry-panosomal
agent. The present research reports on the in vitro antitrypanosomal activities of eleven
imido-substituted 1,4-naphthoquinone analogs on T. cruzi epimastigotes.
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MATERIALS AND METHODS
Chemical compounds
Eleven imido-substituted 1, 4-naphthoquinones (Fig. 2) were used in this study.
Chemistry
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The succinimidyl (IMDNQ1), phthalimidyl (IMDNQ2), and dibutytryl (IMDNQ3)
derivatives were synthesized from 2-amino-3-chloro-1,4-naphthoquinone and the
appropriate acid chloride as previously described (Bakare et al., 2003; Berhe et al., 2008).
The morpholine dione analog (IMDNQ4) was synthesized by microwave irradiation of a
mixture of 2-amino-3-chloro-1,4-na-phthoquinone and diglycolyl chloride as depicted in
scheme 1 (Berhe et al., 2008). On the other hand, the bis-(chloroacetyl)-derivative
(IMDNQ11) was prepared by heating 2-amino-3-chloro-1,4-naphthoquinone in excess 2chloroacetyl chloride at high temperatures as shown in scheme 1 (Bakare et al., 2003; Berhe
et al.,2008). The diarylimido-substituted naphthoquinones IMDNQ5 to IMDNQ10 were
synthesized via sodium hydride facilitated bis-acylation of 2-amino-3-chloro-1,4naphthoquinone or 2-amino-3-bromo-1,4-naphtho-quinone as shown in scheme 2. All
reactions were carried out using laboratory grade materials and solvents. Melting points
were determined in open capillary tubes on a Mel-Temp melting point apparatus and are
uncorrected. The IR spectra were recorded on a Perkin Elmer PE 100 spectrometer with an
Attenuated Total Reflectance (ATR) window. The 1H- and 13C-NMR spectra were obtained
on a Bruker Avance 400 MHz spectrometer in deuterated chloroform (CDCl3). Chemical
shifts are in ä units (ppm) with TMS (0.00 ppm) or CHCl3 (7.26 ppm), as the internal
standard for 1H-NMR, and CDCl3 (77.00 ppm) for 13C-NMR. Electro-spray ionization mass
spectrometry was recorded on a Thermo LTQ Orbitrap XL mass spectrometer and
compounds dissolved in acetonitrile containing 0.1% formic acid. The known intermediates
were prepared according to procedures that are reported in the literature. 2-Amino-3-

Arch Pharm Res. Author manuscript; available in PMC 2013 May 29.

Khraiwesh et al.

Page 3

bromo-1,4-naphthoquinone was prepared by refluxing commercially available 2,3dibromo-1,4-naphthoquinone with ammonia/ammonium hydroxide mixture in ethanol.
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Antitrypanosomal activity assay

T. cruzi epimastigotes (Tulahuen CL98 strain) were cultured in liver infusion trypose (LIT)
medium supplemented with 10% fetal bovine serum (FBS) at 28°C, with an inoculum of 1 ×
105 cells/mL. Different concentrations ranging from 0.39–100 µM of the chemical
compounds were added. All assays were carried out in triplicate. Parasites were counted
after 48 h using hemocytometers and the concentration that inhibits the parasite’s
proliferation by 50% (IC50) was calculated for each compound. Nifurtimox (one of two
commercial drugs for Chagas disease) was used as a reference drug.
Cytotoxicity assay
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The cytotoxic effects of the imido-substituted 1, 4-naphthoquinones on Balb/C 3T3 mouse
fibroblasts (clone A31) were quantitatively assessed using a 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. MTT is a yellow tetrazolium salt that is reduced to purple formazan crystals by metabolically active cells. Cells
(2.2 × 104 cells/well) were seeded in a 96-well plate in Improved Minimum Essential
Medium (IMEM). Serial dilutions (0.39–100 µM) of the compounds were added. After 48 h
incubation at 37°C in the presence 5% CO2, the medium was aspirated and the cells were
washed twice to remove traces of chemical compounds. IMEM without phenol containing
10% (v/v) of 3 mg/mL MTT was added to each well. The plates were incubated for 4 h at
37°C followed by aspiration. The plates were dried for 1 h in a 37°C incubator. 100 µL of
0.04 N HCl in isopropanol was added to each well and incubated at room temperature
(27°C) in the dark for 2 h to dissolve the formazan crystals. The absorbance was measured
spectrophotometrically at 570 nm in a plate reader. The concentration that reduces cell
viability by 50% (IC50) was calculated for each compound. The toxicity for mammalian
cells and the activity against T. cruzi were compared by calculating the selectivity index
(SI), which is the ratio of IC50 for fibroblast cells/ IC50 for parasites.
Statistical analysis
All experiments were carried out in triplicate, and the means and standard errors (S.E.) were
determined. Data were analyzed by one way ANOVA and Tukey’s multiple comparison test
using GraphPad PRISM software version 5.00. p < 0.05 was considered significant.
General procedure for the synthesis of arylim-ido-substituted naphthoquinones (IMDNQ5 –
IMDNQ10)
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2-Amino-3-chloro-1,4-naphthoquinone (1.47 mmol) or the 3-bromo-analog was dissolved in
THF (15 mL). NaH (3.08 mmol) was added and the mixture was stirred at room temperature
for 15 min. Appropriate acid chloride (3.08 mmol) was added drop wise, and the resulting
mixture was stirred at room temperature for 24 h. The THF was then evaporated under
vacuum and ice-cooled water added to the residual mixture. The resulting aqueous mixture
was extracted with CH2Cl2 (2 × 30 mL) and the combined organic phase was washed with
water (3 × 15 mL) and saturated NaCl solution (15 mL) and dried over anhydrous MgSO4.
The crude product was purified by triturating in hot ethanol followed by recrystallization in
ethyl acetate and/or column chromatography on silica gel.
N-(3-Bromo-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-fluoro-N-(4fluorobenzoyl)-benzamide (IMDNQ 5)—Yellow solid (66%); m.p. 170–172°C; IR
(cm−1) 1719.23, 1670.56, 1596.69, 1505.57; 1H-NMR (CDCl3) 7.05 (t, 4H, J = 12.0 Hz),
7.77–7.88 (m, 6H), 8.08–8.15 (m, 1H), 8.21–8.27 (m, 1H); 13C-NMR (CDCl3) 115.57,
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115.79, 127.4, 127.71, 130.18, 130.30, 130.33, 130.85, 131.35, 131.44, 134.46, 134.50,
138.52, 146.90, 165.03, 169.91, 176.96, 177.97; ESI MS m/z 517.9785 ([M+Na]+ calcd
517.9815).
N-(3-Bromo-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-2-chloro-N-(2chlorobenzoyl)-benzamide (IMDNQ 6)—Yellow crystal (34%); m.p. 232–234°C; IR
(cm−1) 1728.78, 1688.76, 1671.10, 1588.22, 1468.70; 1H-NMR (CDCl3) 7.13 (d, 2H, J = 7.9
Hz), 7.21 (dd, 2H, J = 1.6, 7.9 Hz), 7.28 (dd, 2H, J = 1.3, 7.5 Hz), 7.78–7.86 (m, 2H), 7.94
(d, 2H, 5.2 Hz), 8.15–8.21 (m, 1H), 8.22–8.28 (m, 2H); 13C-NMR (CDCl3) 126.65, 127.66,
128.08, 129.63, 130.49, 130.81, 131.23, 132.25, 134.68, 134.80, 140.78, 145.81, 167.57,
177.26, 177.81; ESI MS m/z 549.9240 ([M+Na]+ calcd 549.9224).
4-Chloro-N-(4-chlorobenzoyl)-N-(3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2yl)-benzamide (IMDNQ 7)—Yellow solid (27%); m.p. 212–213°C; IR (cm−1) 1737.38,
1714.75, 1696.91, 1673.62, 1589.20, 1571.10; 1H-NMR (CDCl3) 7.33–7.36 (m, 4H), 7.68–
7.72 (m, 4H), 7.79–7.85 (m, 2H), 8 09–8.11 (m, 1H), 8.20–8.22 (m, 1H); 13C-NMR (CDCl3)
127.72, 127.80, 129.18, 130.34, 130.50, 131.32, 132.52, 134.92, 134.95, 139.67, 142.46,
143.87, 170.40, 177.05, 178.59; ESI MS m/z 505.975 ([M+Na]+ calcd 505.973).
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2-Chloro-N-(2-chlorobenzoyl)-N-(3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2yl)-benzamide (IMDNQ 8)—Yellow solid (49%); m.p. 217–218°C; IR (cm−1) 1720.19,
1681.22, 1618.00, 1588.02; 1H-NMR (CDCl3) 7.10–7.16 (m, 2H), 7.21–7.31 (m, 4H), 7.79–
7.89 (m, 4H), 8.17–8.20 (m, 1H), 8.20–8.26 (m, 1H); 13C-NMR (CDCl3) 126.76, 126.93,
127.60, 127.80, 129.69, 130.54, 130.85, 131.37, 132.36, 132.52, 132.56, 132.75, 134.14,
134.75, 134.91, 142.65, 144.43, 177.13, 178.22; ESI MS m/z 505.9741 ([M+Na]+ calcd
505.9730).
N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-fluoro-N-(4fluorobenzoyl)-benzamide (IMDNQ 9)—Yellow solid (56%); m.p. 284–286°C; IR
(cm−1) 3074.94, 1719.61, 1689.97, 1672.75, 1591.10; 1H-NMR (CDCl3) 7.00–7.06 (m, 1H),
7.75–7.85 (m, 1H), 8.10–8.12 (m, 6H), 8.20–8.22 (m, 4H); 13C-NMR (CDCl3) 115.97,
116.19, 116.41, 126.65, 126.96, 127.67, 127.77, 130.53, 130.57, 130.58, 131.35, 131.62,
131.71, 132.75, 134.88, 142.42, 144.13, 164.14, 166.68, 170.33, 177.13, 178.63; ESI MS m/
z 474.034 ([M+Na]+ calcd 474.032).
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3-Chloro-N-(3-chlorobenzoyl)-N-(3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2yl)-benzamide (IMDNQ 10)—Yellow solid (31%); m.p. 258–260°C; IR (cm−1) 3075.36,
1713.64, 1698.11, 1672.50, 1591.48, 1571.31; 1H-NMR (CDCl3) 7.27–7.31 (t, J = 7.85 Hz,
2H), 7.42–7.45 (ddd, J = 1.03, 2.09, 8.07 Hz, 2H), 7.60–7.63 (td, J = 1.07, 7.68 Hz, 2H),
7.70–7.71 (t, J = 1.82 Hz, 2H), 7.80–7.85 (m, 2H), 8.11–8.14 (m, 1H), 8.21–8.23 (m,
1H); 13C-NMR (CDCl3) 127.02, 127.93, 128.03, 129.34, 130.21, 130.75, 131.55, 133.29,
135.14, 135.21, 136.06, 143.00, 143.84, 170.20, 177.25, 178.66; ESI MS m/z 505.9741 ([M
+Na]+ calcd 505.9730).

RESULTS AND DISCUSSION
The antitrypanocidal activities, cytotoxicity, and selectivity indices of the eleven imidosubstituted 1,4-naphthoquinones and nifurtimox are summarized in Table I. Compared to
nifurtimox (IC50 = 10.67 µM), all the imido-naphthoquinone analogs (IMDNQ1 –
IMDNQ11) studied are significantly more potent on T. cruzi with IC50 values ranging from
0.7 µM to 6.1 µM (p < 0.05, Fig. 3). A cytotoxicity study on a Balb/C 3T3 mouse fibroblast
cell line showed that three of the compounds, IMDNQ1, IMDNQ2, IMDNQ10, are
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considerably less cytotoxic than nifurtimox (Fig. 4). As shown in Fig. 5, these three analogs
(IMDNQ1, IMDNQ2, IMDNQ10) and the more cytotoxic IMDNQ3 displayed selectivity
indices of 60.25, 53.97, 275.30, and 31.83, respectively, rendering them significantly more
selective in inhibiting the parasite’s growth than nifurtimox (selectivity index = 10.86).
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In the pursuit of novel selective antitrypanosomal agents with little or no toxicity to
mammalian cells, eleven imido-substituted 1,4-naphthoquione analogs were developed as a
new class of antitrypanosomal agent. The study of these cyclic and acyclic imido-substituted 1,4-naphthoquinone derivatives on T. cruzi revealed potent antitrypanosomal
properties against T. cruzi by inhibiting their proliferation in vitro. All the eleven imidosubstituted 1,4-naphthoquinone displayed more potent antitrypanosomal activities than the
clinically used nifurtimox. Further, comparison of the antitryponosomal activities with
cytotoxicity on a Balb/C 3T3 mouse fibroblast cell line revealed that four of these
compounds, IMDNQ1, IMDNQ2, IMDNQ3, and IMDNQ10 show considerably better
selectivity than nifurtimox as seen from the selectivity indices values (Table I and Fig. 5).
Of the compounds studied, the structure-activity relationship revealed that dibu-tyrylamino
derivative (IMDNQ3) is the most potent with an IC50 value of 0.7 µM against T. cruzi.
However, this compound is among the most cytotoxic to the mouse fibroblast cells (IC50 =
21.67 µM) in this study, and as shown in previous reports of the cytotoxicity of compound
IMDNQ3 on different human cancer cell lines (Bakare et al., 2003; Berhe et al., 2008). The
potent activity in the antitrypanosomal study nevertheless provided IMDNQ3 with a good
selectivity index of 31.83. On the other hand, two of the cyclic imido-na-phthoquinone
analogs, IMDNQ1 and IMDNQ2, while showing potent antitrypanosomal activities (IC50 =
2.77 µM for IMDNQ1 and 4.89 µM for IMDNQ2), are relatively non-toxic to the mouse
fibroblast cell (IC50 values of 165.9 µM for IMDNQ1 and 253.7 µM for IMDNQ2). This
selectivity means that the two compounds are of greater value and interest than the most
potent antitrypanosomal compound, IMDNQ3. Of greater interest is the selectivity of
IMDNQ10 (selectivity index of 275.3), which showed potent antitrypanosomal activity with
an IC50 value of 2.23 µM against T. cruzi, while being non-cytotoxic to the mouse fibroblast
cell (IC50 value of 610.9 µM). Compound IMDNQ10 is a diaryl imido analog with metachloro-substituent on each of the imide aryl groups and thus significantly differs from the
two cyclic imido-derivatives IMDNQ1 and IMDNQ2. The other cyclic imido-analog
IMDNQ4 is also potent against T. cruzi with an IC50 value of 4.93 µM, but is more
cytotoxic in the mouse fibroblast cell (IC50 = 35.50 µM). This greater cytotoxicity could be
due to the presence of the oxygen atom in the cyclic imide moiety which could facilitate
further hydrogen-bonding to molecular targets in the mouse fibroblast cell, rendering it more
susceptible to the cytotoxic activity of compound IMDNQ4. Comparison of all the diaryl
imido derivatives (IMDNQ5 to IMDNQ10) showed that, with the exception of compound
IMDNQ10, all the other diarylimido compounds (IMDNQ5 to IMDNQ9) are reasonably
cytotoxic to the mouse fibroblast cells and consequently show poorer selectivity indices
(Table I, Fig. 5). The non-cytotoxic diarylimido naphthoquin-one IMDNQ10 possess a
chloro group in the meta-position of each aryl group in the diarylimido-moiety, while the
other analogs possess a chloro or fluoro group in either a para- or ortho-position. The reason
for the observed difference in cytotoxicity between a chloro group in a meta- (IMDNQ10),
para- (IMDNQ7) or ortho- (IMDNQ8) position in these compounds is not immediately
apparent; however, it could be suggested that the presence of the chloro group in a metaposition could have distorted the interaction of compound IMDNQ10 with a potential
binding site necessary for cytotoxicity in the mouse fibroblast cells. The replacement of the
3-chloro group on the 1,4-naphtho-quinone ring with a 3-bromo group did not drastically
affect the activities and selectivity indices of these compounds, as can be seen in the activity
and selectivity of compound IMDNQ6 versus IMDNQ8 and also compound IMDNQ5
versus IMDNQ9 (Table I, Fig. 2). There appears to be a slight increase in antitrypano-somal
activity when the 3-chloro group is substituted with a 3-bromo group as seen in compounds
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IMDNQ9 (IC50 = 4.07 µM) and IMDNQ5 (IC50 = 2.27 µM). This can also be seen when the
activity of compound IMDNQ8 (IC50 = 2.67 µM) is compared with that of IMDNQ6 (IC50 =
1.51 µM). Similarly, there is a corresponding slight increase in cytotoxicity on the Balb/ C
3T3 mouse fibroblast cell line when the 3-chloro group is substituted with a 3-bromo group,
as again can be seen in compound IMDNQ9 (IC50 = 21.83 µM) vs IMDNQ5 (IC50 = 12.83
µM) and in compound IMDNQ8 (IC50 = 26.50 µM) vs IMDNQ6 (IC50 = 14.17 µM).
Comparison of compounds IMDNQ7 and IMDNQ9 revealed that substituting the parachloro group in the diarylimido moiety of IMDNQ7 with the smaller and more
electronegative fluoro group in IMDNQ9 slightly reduced both the antitrypanosomal and
cytotoxic activities (Table I). The bis-chloroacetylamino derivative IMDNQ11 is the least
potent antitrypanosomal imido naphthoquinone in this study with an IC50 value of 6.10 µM.
This compound is also the least selective analog with a selectivity index of 3.20 (Table I,
Fig. 5).
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All the imido-substituted naphthoquinones studied are more potent antitrypanosomal agents
than the clinically used nifurtimox; however, only four compounds, IMDNQ1, IMDNQ2,
IMDNQ3 and IMDNQ10 with selectivity indices of 60.25, 53.97, 31.83, and 275.3,
respectively, are significantly more selective than nifur-timox (selectivity index of 10.86).
Further, three of these compounds are relatively non-cytotoxic to the Balb/C 3T3 mouse
fibroblast cell line with IC50 values of significantly more than 100 µM. These compounds
thus represent a novel class of selective antitrypano-somal agents for further drug
development. We are currently studying the mechanism of antitrypano-somal activity of this
imidonaphthoquinone class of compounds.
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Fig. 1.

Structures of nifurtimox, benznidazole and the naturally occurring naphthoquinone
compound lapachol
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Fig. 2.

Structures of imido–substituted 1,4-naphthoquinone derivatives
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Fig. 3.

Trypanocidal effects of the imido-substituted 1, 4-naphthoquinones on T. cruzi. Results are
expressed as the means ± S.E. of three experiments. *p < 0.05, **p < 0.01, ***p < 0.001
compared with Nifurtimox
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Fig. 4.

Cytotoxicity of the imido-substituted 1, 4-na-phth-oquinones on Balb/C 3T3 mouse
fibroblasts. Results are expressed as the means ± S.E. of three experiments. ***p < 0.0001
compared with Nifurtimox
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Fig. 5.

Selectivity indices of the imido-substituted 1, 4-na-phthoquinones. Results are expressed as
the means ± S.E. of three experiments. **p < 0.01, ***p < 0.0001 compared with
Nifurtimox
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Scheme 1.

Synthesis of imido-substituted naphthoquinone derivatives IMDNQ4 and IMDNQ11
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Scheme 2.

Synthesis of diaryimido-naphthoquinone derivatives IMDNQ5 to IMDNQ10
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Table I

Trypanocidal activity, cytotoxicity, and selectivity indices of the chemical compounds
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Nifurtimox

Antitrypanocidal
activity
IC50 (µM)

Cytotoxicity
IC50 (µM)

Selectivity index
(Cytotoxicity/
Activity)

10.67 ± 1.01

114.0 ± 1.03

10.86 ± 0.93

IMDNQ1

2.77 ± 0.15

165.9 ± 1.24

60.25 ± 2.79

IMDNQ2

4.83 ± 0.60

253.7 ± 1.87

53.97 ± 5.95

IMDNQ3

0.70 ± 0.10

21.67 ± 1.45

31.83 ± 3.17

IMDNQ4

4.93 ± 0.64

35.50 ± 1.76

7.43 ± 0.97

IMDNQ5

2.27 ± 0.15

12.83 ± 0.73

5.70 ± 0.06

IMDNQ6

1.51 ± 0.01

14.17 ± 1.42

9.43 ± 0.94

IMDNQ7

1.27 ± 0.15

17.83 ± 2.21

14.23 ± 1.62

IMDNQ8

2.67 ± 0.33

26.50 ± 1.61

10.17 ± 0.97

IMDNQ9

4.07 ± 0.23

21.83 ± 1.88

5.43 ± 0.69

IMDNQ10

2.23 ± 0.15

610.9 ± 10.27

275.3 ± 13.73

IMDNQ11

6.10 ± 0.38

19.67 ± 3.71

3.20 ± 0.44
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Each value represents the mean ± S.E. of three experiments.
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